Thumb_logo_white Discover Create Go Pro
Log In / Sign Up
How Alum adjuvant boost antigenic response
Clean
July 21, 2008 04:18 AM PDT

In this edition, I discuss the recent paper of Kool et al submitted to JEM, and where the authors evaluate the effect of aluminum adjuvant in antigen response.

The authors found thad adjuvant mix results in the mobilization of phagocytes and monocytes to the peritoneal cavity upon i.p. injection of antigen, boosting antigen specific T cell response in the draining lymph nodes

The most important observation found by authors was that inflammatory monocytes mobilized by adjuvant differentiate into matured dendritic cells and such cells are key elements in the antigen T cell response.

A great reading...

For reference please check the mouse lymph node localizations on this link.

See you soon and have a nice listening

Efective anti-cancer immunotherapy with CD4 T cell clone
Clean
June 30, 2008 03:45 PM PDT

In this edition, I describe the manuscript published by the group of Cassian Yee to the New England Journal of Medicine entitled "Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1", that can be found in the volume 358 page 2698, of 2008 year series.

Anti-tumor role of {gamma}{delta} T cells in expontaneous prostate tumors
Clean
May 28, 2008 06:55 AM PDT

In this podcast I will describe a recent manuscript submitted by Liu et al to journal of Immunology 2008; 108:6044 , where {gamma}{delta} T cell knock-out mice were evaluated under situation of expontaneous prostate cancer (crossed with TRAMP mice) and in addition {gamma}{delta} T cells were also used in adoptive therapy settings against established tumors and metastatic disease.

The authors show that under the experimental design setting that {gamma}{delta} T cells play a certain role in controlling tumor growth, by reducing the tumor burden and aggressiveness.

See you next time

NKG2D mediated tumor immunity
Clean
May 08, 2008 02:24 AM PDT

Hi folks,

Today I will do a short overview of a major manuscript published recently in journal immunity that presents data concerning the evaluation of NKG2D knock-out mice in the context of expontaneous tumor development.

The format of the podcast has changed to fit in my time constrains. Let me know what do you think.

See you soon, and thanks for listening

N-acetyllactosamine (lacNAC) reverts human TIL anergy ex vivo.
Clean
April 20, 2008 03:50 PM PDT
Hello

In this edition of the podcast I will discuss a paper published by Demotte and collaborators published this year in the journal Immunity "Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes" vol 28, pag 414 of April 2008.

In this paper the authors show that LacNAC can compete for galectin-3 binding freeing TCR from TIL to colocalize with CD8 and allow the recovery of efector functional on ex vivo freshly isolated TIL from ovarian cancer and gastric cancer.
See you next time.
Immune pressure results in mutation of DRIP derived epitope in SIV
Clean
February 19, 2008 12:53 PM PST
Hello

Welcome to the first edition of the Tumor Immunology Round Table podcast.

In this edition I present you an very interesting and novel finding recently published in Journal of Experimental Medicine by Maness et al: the immune system induces the mutation by the SIV of an DRIP (defective ribosomal product) that is immunogenic and induces strong dominant responses in monkeys infected with SIV. The DRIP derives from a alternative reading frame of the gene env.

The mutation specifically target the immunogenic peptide presented my the rhesus macaques haplotype mamu-B*17, as it doesn't affect the env sequence (sinonimous mutation). The mutation renders the peptide with much lower affinity than the wild type peptide and therefore the virus escape the immunological control.

That's a great example of immunological editing of virus and the conclusions can be easily extrapolated to cancer immune editing.
A diversified memory repertoire from a single naive T cell
Clean
March 04, 2008 11:22 PM PST
 Hello

In this edition of the podcast I will discuss a paper published by Stemberger and collaborators in the journal Immunity called "A single naive CD8+ T cells precursor can develop into diverse effector and memory subset" vol 27, pag 987 of December 2007.

In this very interesting paper the authors redraw the concepts of memory T cells differentiation from naive T cells, developping a successfull model of transfer of an single naive T cell precursor. The paper shows that this single antigen specific naive T cell precursor can give rise to an diversified memory T cell responses including all subsets (central memory (CD62L positive, CD127 posit) and effector memory (CD62L negative, CD127 positive) T cells) upon antigen challenge.

Importantly the kind of memory responses were equivalent in frequency to the ones generated by the host mice (containing a normal size naive pool of antigen specific T cells) against an antigenic protein.

See you next time.

PS: The audio has "clicks" artifacts that I don't know the origin. I apologize for that.
Immune pressure results in mutation of DRIP derived epitope in SIV
Clean
February 19, 2008 12:53 PM PST
Hello

Welcome to the first edition of the Tumor Immunology Round Table podcast.

In this edition I present you an very interesting and novel finding recently published in Journal of Experimental Medicine by Maness et al: the immune system induces the mutation by the SIV of an DRIP (defective ribosomal product) that is immunogenic and induces strong dominant responses in monkeys infected with SIV. The DRIP derives from a alternative reading frame of the gene env.

The mutation specifically target the immunogenic peptide presented my the rhesus macaques haplotype mamu-B*17, as it doesn't affect the env sequence (sinonimous mutation). The mutation renders the peptide with much lower affinity than the wild type peptide and therefore the virus escape the immunological control.

That's a great example of immunological editing of virus and the conclusions can be easily extrapolated to cancer immune editing.